|1.||Nehlig, Astrid: 5 articles (05/2014 - 01/2007)|
|2.||Zannikos, Peter: 4 articles (09/2012 - 01/2007)|
|3.||Novak, Gerald: 4 articles (10/2011 - 08/2009)|
|4.||Koning, Estelle: 3 articles (05/2014 - 07/2011)|
|5.||Ferrandon, Arielle: 3 articles (05/2014 - 07/2011)|
|6.||François, Jennifer: 3 articles (07/2011 - 01/2007)|
|7.||Zhao, Boyu: 3 articles (08/2009 - 01/2007)|
|8.||Novak, Gerald P: 3 articles (02/2009 - 01/2007)|
|9.||Cassel, Jean-Christophe: 2 articles (05/2014 - 07/2013)|
|10.||Akimana, Gladys: 2 articles (05/2014 - 07/2013)|
06/01/2015 - "Freely moving rats receiving closed-loop direct stimulation therapy with ondemand intracerebral carisbamate delivery experienced a significant reduction in seizure frequency (p < 0.001) and minimized seizure frequency variability during the final 50% of the therapy/recording session compared with closed-loop stimulation therapy alone. "
03/01/2010 - "Carisbamate 400 mg/day was effective in patients with refractory partial-onset seizures in one of these global studies. "
03/01/2009 - "Phase IIb clinical trials of carisbamate demonstrated efficacy against partial onset seizures; however, its mechanisms of action remain unknown. "
04/01/2011 - "A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures."
03/01/2010 - "Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials."
05/01/2007 - "Randomized, controlled studies of carisbamate in epilepsy patients inadequately controlled by their existing AED therapy are warranted."
06/01/2015 - "On-demand pulsatile intracerebral delivery of carisbamate with closed-loop direct neurostimulation therapy in an electrically induced self-sustained focal-onset epilepsy rat model."
03/01/2009 - "Carisbamate is being developed for adjuvant treatment of partial onset epilepsy. "
10/01/2007 - "This drug profile will focus on the development of carisbamate in epilepsy."
10/01/2007 - "Carisbamate, a new carbamate for the treatment of epilepsy."
|3.||Brain Injuries (Brain Injury)
01/01/2007 - "To evaluate the therapeutic efficacy of two antiepileptic compounds, RWJ-333369 and RWJ-333369-A in a well-established experimental model of lateral fluid percussion (FP) traumatic brain injury (TBI) in the rat. "
10/01/2008 - "Carisbamate prevents the development and generation of epileptiform discharges and is neuroprotective when administered following SE-like injury in vitro and may offer a novel treatment to prevent the development of epileptiform discharges following brain injuries."
10/01/2007 - "Data from preclinical brain injury studies with carisbamate and the analog RWJ-333369-A have also been reported. "
01/01/2007 - "The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury."
04/01/2011 - "Dizziness was the most common treatment-emergent adverse event, with a higher incidence (≥ 5% difference) in the combined carisbamate group (31%) than placebo (9%); the incidence was higher with carisbamate 1,200 mg (32%, n = 58) than with carisbamate 800 mg (30%, n = 53). "
05/01/2007 - "The duration of action was dose-related and long-lasting, with clinically significant reductions of photosensitivity observed for up to 32 h after doses of 750 or 1000 mg. Carisbamate was generally well tolerated, with dizziness and nausea reported more frequently after active drug than placebo. "
04/01/2014 - "Neither carisbamate (all 3 studies) nor pregabalin (study 3) significantly differed from placebo, although multiple secondary end points showed significant improvement in efficacy with carisbamate in studies 1 and 2. Dizziness was the only treatment-emergent adverse event occurring at ≥10% difference in carisbamate groups versus placebo (study 1: 12% vs. 1%; study 3: 14% vs. 4%; study 2: 1% vs. 2%). "
10/01/2007 - "The most frequently reported side effects associated with carisbamate are dizziness, headache, somnolence and nausea. "
09/01/2012 - "Adverse events with the highest incidence were dizziness (50%) and headache (50%) in study 1 and somnolence (56%) in study 2. Warfarin exposure and international normalized ratio were unaffected by coadministration of carisbamate 200 mg or 600 mg twice-daily. "
|5.||Status Epilepticus (Complex Partial Status Epilepticus)
05/01/2014 - "Twenty of them received a carisbamate treatment for 7 days, starting 1 h after status epilepticus onset. "
05/01/2008 - "Whole-cell current clamp techniques were used to determine the effects of carisbamate on spontaneous recurrent epileptiform discharges (SREDs, in vitro epilepsy), depolarization-induced sustained repetitive firing (SRF) and low Mg(2+)-induced continuous high frequency spiking (in vitro status epilepticus). "
03/01/2011 - "Carisbamate (CRS) exhibits broad acute anticonvulsant activity in conventional anticonvulsant screens, genetic models of absence epilepsy and audiogenic seizures, and chronic spontaneous motor seizures arising after chemoconvulsant-induced status epilepticus. "
07/01/2013 - "A comprehensive behavioral evaluation in the lithium-pilocarpine model in rats: effects of carisbamate administration during status epilepticus."
07/01/2011 - "In conclusion, carisbamate is able to induce strong neuroprotection and affect the nature of epileptogenic events occurring during and after lithium-pilocarpine status epilepticus, reflecting marked insult- and disease-modifying effects."
|2.||Kainic Acid (Kainate)
|7.||Sodium Channels (Sodium Channel)
|9.||Neurotransmitter Agents (Neurotransmitter)